logo
Plus   Neg
Share
Email

VF Corp. Guides FY21 Above Estimates - Quick Facts

While reporting financial results for the second quarter on Friday, VF Corp. (VFC) provided adjusted earnings and revenue guidance for the full-year 2021, above analysts' expectations.

For fiscal 2021, the company now projects adjusted earnings to be at least $1.20, reflecting a decrease of approximately 55 percent from last year. It also expects full-year revenues of at least $9.0 billion, reflecting a decrease of approximately 14 percent on an adjusted basis, including low single-digit growth in the second half driven by a return to growth in the fourth quarter.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $1.12 per share on revenues of $8.83 billion for the year. Analysts' estimates typically exclude special items.

Further, VF's Board of Directors declared a 2 percent higher quarterly dividend of $0.49 per share, payable on December 21, 2020, to shareholders of record on December 10, 2020.

Subject to approval by its Board of Directors, VF intends to continue to pay its regularly scheduled dividend and is not currently contemplating the suspension of its dividend.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
British retailer Arcadia fashion group, owned by Philip Green, has entered into administration as it seeks protection from creditors following significant business loss during the coronavirus pandemic. The administration is likely to affect around its 13,000 employees. The retailer, which owns eight high street and fashion retails brands, is now seeking buyers for its brands. Data giant S&P Global Inc. has agreed to acquire information and analytics company IHS Markit Ltd. in an all-stock deal, the two companies said Monday. The deal values IHS Markit at an enterprise value of $44 billion, including $4.8 billion of net debt. Shares of IHS Markit are gaining almost 6 percent following the news. The deal is the biggest in 2020. Moderna, Inc. (MRNA) said it will apply for an Emergency Use approval of its Covid vaccine as the latest study showed that the vaccine candidate is 94.1% effective to prevent Covid-19. The company said there have been no serious safety concerns identified. The company will file for an Emergency...
Follow RTT